People · Operator
Named in public records as an officer, director or promoter · active 2014–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. | — | Pharmaceuticals | Series C | $128.2M | $2.1B | 2019 |
| Potenza Therapeutics, Inc. | — | Pharmaceuticals | Series B | $35.0M | $170.0M | 2014 |
| Vesuvius Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $10.2M | $316.7M | 2014 |
| Trieza Therapeutics, Inc. | — | Pharmaceuticals | Series A | $6.0M | $185.8M | 2016 |
Daniel Hicklin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Hicklin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Luke Evnin | 4 | 12 |
| David Cordo | 4 | 6 |
| Arnold Oronsky | 2 | 10 |
| Sakae Asanuma | 2 | 6 |
| Phil Gutry | 2 | 4 |
| Briggs Morrison | 1 | 8 |
| Christoph Westphal | 1 | 8 |
| Derek DiRocco | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| Elise Wang | 1 | 2 |
| Shunichiro Matsumoto | 1 | 1 |
| Cynthia Seidel-Dugan | 1 | 1 |
| James Wescott | 1 | 1 |
| Reid Leonard | 1 | 1 |
| Patrick Baeuerle | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.